Arterium is the principal scientific partner of the People and Health – Uzbekistan Congress

Arterium is the principal scientific partner of the People and Health – Uzbekistan Congress

On 3-4 April 2014 Tashkent hosted the first national republican congress with international participation People and Health – Uzbekistan. Arterium Corporation became the event’s principal scientific partner.

This congress is one of the largest specialized events, bringing together the leading medical scientists and healthcare professionals from Russia, Ukraine, Belarus and United Kingdom and also practicing physicians and heads of specialized ministries – in short, all those responsible for the country’s public health.

The forum’s goal is to implement advanced diagnostics and treatment methods in the daily medical practice and exchange knowledge among physicians specializing in the field of therapy. The event has gathered over 4000 professionals of various specializations: cardiologists, therapists, neurologists, pediatricians, gynecologists, urologists, and general practitioners.

The congress’s scientific program included plenary sessions, lectures, master classes, thematic scientific symposiums and sessions. The attendees shared their knowledge and experience in using medicinal products on the basis of evidence-based medicine in cardiology, neurology, gastroenterology, urology, pediatrics, and obstetrics and gynecology.

The Arterium Corporation stand presented over-the-counter drugs (Urolesan, Sedavit, Difluzol, Herpevir), cardio-neurological drugs (L-lysine aescinate, Thiotriazolin, Thiocetam, Sonnat), and antibiotics (Azimed and Inspiron). These drugs are represented on pharmaceutical market of the Republic of Uzbekistan and enjoy high demand among the republic’s medical institutions and drugstore chains.

Дякуємо за звернення!

Ваша форма успішно відправлена. Якщо у вас виникли додаткові питання, будь ласка, заповніть форму на сайті або зателефонуйте нам

Pharmacovigilance

If you have any information about an adverse reaction and/or lack of efficacy of an Arterium Corporation drug, please fill out the form: